Cambridge Cognition Holdings PLC Investor Webinar and Analyst Briefing

TIDMCOG

Cambridge Cognition Holdings PLC

26 April 2023

REACH

Cambridge Cognition Holdings Plc

(" Cambridge Cognition" or the "Company")

Investor Webinar and Analyst Briefing

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, will be announcing the Company's preliminary financial results for the year ended 31 December 2022 on Wednesday 3 May 2023 and is pleased to provide details of an investor webinar and analyst briefing being held on that day.

Investor Webinar

Cambridge Cognition's management will be hosting an online presentation and Q&A session at 5.30 p.m. BST on Wednesday 3 May 2023. This session is open to all existing and prospective shareholders. Those wishing to attend should email [e-mail] and they will be provided with log in details.

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: [e-mail] .

Analyst Briefing

The Company's management will be hosting a presentation for analysts on the day of results at 9:30 a.m. BST, those who wish to attend the briefing should register their interest with Zach Cohen at [e-mail] or on 020 3934 6637.

Enquiries

 
Cambridge Cognition Holdings Plc              Tel: [phone] 
 Matthew Stork, Chief Executive Officer        [e-mail] 
 Stephen Symonds, Chief Financial Officer 
Panmure Gordon (UK) Limited (NOMAD and Joint  Tel: [phone] 
 Broker)                                       (Corporate Finance) 
 Freddy Crossley / Emma Earl                   (Corporate Broking) 
 Rupert Dearden 
Dowgate Capital Limited (Joint Broker)        Tel: [phone] 
 David Poutney / James Serjeant 
IFC Advisory Ltd (Financial PR and IR)        Tel: [phone] 
 Tim Metcalfe / Graham Herring / Zach Cohen    [e-mail] 
 

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABIGDSRSDDGXU

(END) Dow Jones Newswires

April 26, 2023 02:00 ET (06:00 GMT)